Hyponatremia frequently poses a therapeutic challenge in acute decompensated heart failure (ADHF). Treating physicians should differentiate between depletional versus dilutional hyponatremia. The former is caused by diuretic agents, which enhance sodium excretion, often with concomitant potassium/magnesium losses. This can be treated with isotonic saline, whereas potassium/magnesium administration may be helpful if plasma concentrations are low. In contrast, as impaired water excretion, rather than sodium deficiency, is the culprit in dilutional hyponatremia, isotonic saline administration may further depress the serum sodium concentration. Because free water excretion is achieved by continuous sodium reabsorption in distal nephron segments with low water permeability, diuretic agents that impair this mechanism (e.g., thiazide-type diuretic agents and mineralocorticoid receptor antagonists) should be avoided, and proximally acting agents (e.g., acetazolamide and loop diuretic agents) are preferred. Vasopressin antagonists, which promote low water permeability in the collecting ducts and, hence, free water excretion, remain under investigation for dilutional hyponatremia in ADHF. (J Am Coll Cardiol 2015;65:480-92)
H yponatremia, defined as a serum sodium (Na þ ) concentration <135 mEq/l, is the most common electrolyte disorder in hospitalized patients (1) . Both admission and hospitalacquired hyponatremia are associated with an increased risk for adverse outcomes, including prolonged hospital stay, need for discharge to a shortor long-term care facility, and all-cause mortality (2) . In a subanalysis from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry, including 47,647 patients with acute decompensated heart failure (ADHF), hyponatremia was present in w20% upon admission (3) . In addition, the incidence of hospital-acquired hyponatremia during decongestive treatment for ADHF is probably w15% to 25% (4, 5) . Hyponatremia frequently poses an important therapeutic challenge in ADHF because simple administration of the depleted ion (as with other deficiencies) cannot be easily performed, and there is an obvious concern for harmful fluid overload. Moreover, the pathophysiology of hyponatremia in ADHF is often dilutional, rather than depletional (6, 7) .
Importantly, ubiquitous use of powerful Na Table 1 provides a summary of the pathophysiology of hyponatremia in ADHF.
DILUTIONAL HYPONATREMIA. It is generally assumed that hyponatremia in ADHF is more often a problem of impaired water excretion than Na þ depletion (6, 7) . hypertonicity (8) . In healthy, normally hydrated persons, circulating AVP levels are very low (w1 pg/ml) because of its rapid degradation and excretion by the liver and kidneys (t 1/2 ¼ 15 to 20 min) (9) . Consequently, hepatic dysfunction and renal insufficiency may contribute to increased plasma levels of AVP in ADHF. AVP exerts its water-retaining effects primarily through stimulation of high-affinity V 2 receptors in the collecting ducts of the nephron ( Figure 1 ) (9). V 2 stimulation increases both the synthesis and availability of aquaporin-2 channels on the luminal side of these collecting ducts, which otherwise have low water permeability (10) . The hypertonic environment of the renal interstitium subsequently provides a strong impetus for water reabsorption, resulting in decreased water excretion and, consequently, less diuresis. Importantly, this system is very sensitive to small changes in plasma AVP levels, which are difficult to detect, even by modern assays (11) . At higher concentrations, the low-affinity V 1a receptor, which is expressed in the liver, collection ducts, and vasa recta of the nephron, is stimulated ( Figure 1 ).
This further enhances hypertonicity in the renal interstitium-hence antidiuresis-through increased hepatic urea production, improved medullary urea reabsorption in the collecting ducts, and reduced blood flow through the vasa recta ( Figure 1) (12,13) . The vasa recta are straight capillaries in the renal medulla with a hairpin loop. They receive a lower proportion of blood flow compared with the renal cortex, especially during antidiuresis. This is important, as high blood flow through the vasa recta washes out the tonicity gradient from the renal cortex toward the medulla, which is needed to concentrate the urine. Finally, another effect of V 1a receptor stimulation is promotion of prostaglandin synthesis in the collecting ducts. This counteracts V 2 effects on aquaporin-2, thus stimulating water excretion (14) . This latter effect may explain why some heart failure patients demonstrate a normal response to water loading, with production of adequately diluted urine, despite having elevated plasma AVP levels (15) .
N o n o s m o t i c a r g i n i n e v a s o p r e s s i n r e l e a s e i n h e a r t f a i l u r e . Several studies have demonstrated that AVP levels are generally elevated in heart failure (16) (17) (18) . Moreover, aquaporin-2 expression was markedly up-regulated in a rat model of congestive heart failure (19) , which would be expected to increase water permeability and reabsorption in the collecting ducts of the nephron. It is tempting to speculate that both events are causally related and promoting excessive free water reabsorption, leading to hyponatremia in ADHF. Certainly, baroreceptor activity, sympathetic overdrive, and angiotensin II, all stimulated by decreased effective circulatory Verbrugge et al.
Hyponatremia in Decompensated Heart Failure volume in ADHF, fuel nonosmotic AVP release, as well as thirst and thus free water intake (20) . Importantly, they also increase the sensitivity of osmotic AVP release ( Figure 2A) . Indeed, compared with healthy volunteers, ADHF patients show a more pronounced increase in plasma AVP levels with osmotic loading (21) . In contrast to this osmotic AVP release, which increases linearly and with very small changes in serum osmolality, nonosmotic AVP release is exponential ( Figure 2B ). Thus, isotonic plasma volume reductions of 5% to 10% will have little effect on AVP secretion, whereas reductions of 20% to 30%, resulting in baroreceptor activation and angiotensin II stimulation, may cause plasma levels many times higher than necessary to produce maximal antidiuresis (50 to 100 pg/ml) (22) . Importantly, at these high levels, AVP has potent V 1a -mediated vasoconstrictor effects that may contribute to hemodynamic deterioration in ADHF (23) .
Insufficient tubular flow through diluting segments of the distal nephron. Healthy kidneys are able to dilute urine to an osmolality as low as 30 to 60 mOsm/l, w5-to 10-fold lower than serum osmolality (24) . However, micropuncture studies have demonstrated that tubular fluid osmolality is quite similar (w150 mOsm/l) at the level of the macula densa during antidiuresis versus water diuresis (25) . Thus, urine dilution depends heavily on the tubular function of more distal parts of the nephron (i.e., distal convoluted tubules and collecting ducts). Free water excretion is achieved by these segments through continued solute reabsorption, primarily through the thiazide-sensitive Na þ /chloride cotransporter and aldosterone-sensitive epithelial sodium channels (ENaCs), in the presence of low water permeability (24, 26) . Importantly, less sodium is reabsorbed by ENaCs in conditions of low tubular flow, irrespective of aldosterone levels (27) . Consequently, if more sodium is retained in the tubular lumen, free water excretion is restricted. The ability of the kidneys to excrete free water is, therefore, directly dependent on: 1) the amount of tubular fluid offered to the distal nephron; and 2) the relatively low water permeability of this segment, which can only be overcome by insertion of aquaporin-2 channels through AVP stimulation. For instance, a healthy person with a glomerular filtration rate (GFR) of 180 l/day (125 ml/min), of which 10% reaches the distal convoluted tubules and with total AVP suppression, would be able to drink w18 l (10% of 180 l) over the course of a day without developing hyponatremia ( Figure 3A ).
Yet, with the GFR lowered to 43.2 l/day (30 ml/min), and only 5% distal tubular flow because of increased proximal reabsorption in ADHF, maximal water intake without hyponatremia development would be decreased tremendously to 2.16 l/day (5% of 43.2 l/day) (28, 29) . The latter is even an overestimate, as it presumes that water permeability in the distal nephron is as low as with total AVP suppression, which is clearly not the case in ADHF ( Figure 3B ). An intriguing study by Bell et al. (30) further supports the concept of decreased distal nephron flow in AHDF. In this study, free water excretion was increased in ADHF patients with hyponatremia after infusion of 5% mannitol, an osmotic diuretic that enhances tubular flow through the DEPLETIONAL HYPONATREMIA. Because increased Na þ avidity characterizes heart failure from the very beginning and is exacerbated by unrestrained neurohumoral up-regulation, Na þ depletion is relatively rare in ADHF not treated with diuretic agents (33, 34) . Still, osmotic diuresis because of hyperglycemia in the case of severe uncontrolled diabetes, gastrointestinal losses, and third-space losses may all contribute to a negative Na þ balance, especially if patients adhere scrupulously to the salt-restricted diets recommended by the guidelines (35) (36) (37) . One group called these diets into question, demonstrating that heart failure patients adhering to such diets experienced increased hospitalizations and a higher mortality rate (38) (39) (40) . However, it should be noted that these patients also received a high dose of diuretic agents (125 to 500 mg furosemide equivalents twice daily), increasing the risk of a negative Na O t h e r d i u r e t i c a g e n t s a n d h y p o n a t r e m i a . Mineralocorticoid receptor antagonists (MRAs) are a cornerstone in the treatment of heart failure with reduced ejection fraction and are promising in selected patients with preserved ejection fraction Neurohumoral activation through angiotensin II and baroreceptor activity increases the amount of AVP release for any given plasma osmolality (20) . In addition, it moves the set-point of total AVP suppression to a lower plasma osmolality, hence promoting hypotonicity. (B) Osmotic versus nonosmotic AVP release: osmotic AVP release is very sensitive and increases linearly, already with very small changes in plasma osmolality (blue curve) (9). Nonosmotic AVP release makes little contribution to overall AVP plasma levels until a 10% to 15% decrease in isotonic plasma volume, after which AVP release increases markedly, resulting in plasma levels many times higher than needed to achieve maximal antidiuresis (red curve) (22) . Abbreviations as in Figure 1 .
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AVP not suppressed:
Through glomerular filtration, a healthy person forms 180 l of tubular fluid each day. As the proximal tubules, thin descending limb, and ascending limb of Henle's loop all have high water permeability, reabsorption in these nephron segments is isotonic, and tonicity of the tubular fluid remains at 285 to 295 mOsm/l, equal to plasma. In contrast, the TAL has low water permeability. Thus, solutes in general and sodium/ chloride in particular are reabsorbed without water, contributing to the hypertonicity of the renal interstitium. Consequently, osmolality is relatively stable (w150 mOsm/l) in the tubular lumen at the level of the macula densa, at which point 90% of reabsorption has occurred, with 10%, or 18 l, remaining on a daily basis (25) . In the case of total AVP suppression, the distal nephron has very low water permeability, while sodium and chloride are continuously reabsorbed; therefore, urine can be diluted up to 30 to 60 mOsm/l. Consequently, almost 18 l of free water excretion can be achieved, which is the maximum a person can drink without developing plasma hypotonicity and hyponatremia. (B) Maximal free water excretion in a patient with heart failure and a GFR of 30 ml/min is considerably lower. In this case, 43.2 l of tubular fluid is formed each day.
As proximal tubular reabsorption increases in heart failure, only 5% or 2.16 l of tubular fluid remains at the level of the macula densa, again with an osmolality of w150 mOsm/l (25) . As AVP is typically increased in heart failure and the minimal medullar tonicity is greater because of poor flow through the vasa recta, the osmotic gradient for water reabsorption is increased in the presence of a more leaky distal nephron. Thus, water is continuously reabsorbed, limiting maximal free water excretion to <1 l. This realistic example illustrates how difficult it can be for a patient to prevent hyponatremia progression with fluid restriction only. GFR ¼ glomerular filtration rate; other abbreviations as in Figure 1 . 
(A) Loop diuretic agents block the sodium/chloride/potassium cotransporter in the TAL, interfering with the generation of hypertonicity in the renal interstitium and decreasing the osmotic gradient that promotes water reabsorption. Loop diuretic agents have no effect on sodium or chloride transport in the distal nephron, which has low water permeability, and they therefore do not interfere with the kidneys' capacity to produce hypotonic urine. (B) Thiazide-type diuretic agents block the sodium/chloride symporter, whereas MRAs inhibit ENaCs in the distal nephron. As both make a negligible contribution to the hypertonicity achieved in the renal interstitium, thiazide-type diuretic agents and MRAs do not interfere with the water reabsorption gradient. However, as sodium and chloride reabsorption in the relatively water-impermeable distal nephron is the mechanism of urinary dilution, this process is impaired, resulting in a higher urinary tonicity and, hence, lower free water excretion compared with loop diuretic agents. ENaC ¼ epithelial sodium channel; MRA ¼ mineralocorticoid receptor antagonists; other abbreviations as in Figure 1 .
Verbrugge et al. Furthermore, magnesium is critical for functioning of the Naþ/potassium ATPase that pumps Na þ out of cells; thus, hypomagnesemia may also exacerbate extracellular Na þ depletion.
INITIAL APPROACH TO HYPONATREMIA IN DECOMPENSATED HEART FAILURE
The Central Illustration presents a stepwise diagnostic and therapeutic approach to hyponatremia in decompensated heart failure. In any patient with hypotonic hyponatremia, it is best to avoid thiazide-type diuretic agents, MRAs, and
ENaC blockers (e.g., amiloride), as these medications interfere directly with the kidneys' capacity to produce hypotonic urine. However, it should be stressed that this advice is purely on the basis of the pathophysiological rationale, as high-quality evidence is lacking. Further, potassium and magnesium stores should be replenished if serum levels are low. We propose aiming for serum potassium levels $4 mEq/l and magnesium levels $1.7 mEq/l ($2 mg/dl) in ADHF patients presenting with hyponatremia, but this cutoff is arguably somewhat arbitrary. A flowchart with a stepwise diagnostic approach to hyponatremia in decompensated heart failure is presented. Therapeutic options are proposed according to the underlying pathophysiological culprit. AVP ¼ arginine vasopressin.
Hyponatremia in Decompensated Heart Failure hyponatremia. Finally, very low urinary Na þ and/or chloride concentrations (<50 mEq/l) are a relatively strong argument for electrolyte depletion.
TREATMENT OF DEPLETIONAL

HYPONATREMIA
As with other deficiencies, pure depletional hyponatremia is easily treated by administration of saline.
Hypertonic saline will correct hyponatremia faster and with a lower water load than isotonic saline, which might be preferred in patients who are already nor- 
with TBW ¼ a Â body weight (kg), and a ¼ 0.6 in children and nonelderly men, 0.5 in nonelderly women and elderly men, and 0.45 in elderly women (62) . Take for example a female patient, 50 years of age and weighing 62 kg, presents with a serum Na þ concentration of 130 mEq/l and a serum K þ of 3.5 mEq/l. This is presumably because of depletion, as she is on a high overload and hyponatremia (75) (76) (77) (78) . Similar data are available for conivaptan, an intravenous agent that antagonizes both the V 2 and V 1a receptors (74, 79, 80) . This promising finding warrants further study in an adequately powered, randomized clinical trial.
LONG-TERM MANAGEMENT OF HYPOTONIC DILU-
TIONAL HYPONATREMIA. W a t e r r e s t r i c t i o n . Water restriction is uniformly recommended by the guidelines in ADHF patients with hyponatremia as it is in others with dilutional hypotonic hyponatremia (35) (36) (37) 59 ). Whilst limiting free water intake certainly aids to prevent a positive free water balance, few data support its long-term efficacy, and adherence might be a problem. Indeed, thirst is a frequent, underrecognized, and distressing problem in heart failure, and many patients may find it difficult to comply with strict water restriction (<1 l) (82) . Nevertheless, a recent study found that ADHF patients with mild hyponatremia had improvements in quality of life with such a strategy (83) .
A V P a n t a g o n i s t s . Although AVP antagonists are highly efficacious for short-term correction of hyponatremia, less is known about their long-term efficacy in providing a sustained correction of serum Na þ levels. In EVEREST, serum Na þ concentration increased more with tolvaptan compared with placebo during in-hospital stay (81) . However, patients also reported feeling thirsty significantly more frequently, and the difference with serum Na þ levels in the placebo group disappeared after instillation of outpatient management, which suggests that patients may have drank more to compensate for increased water losses.
Renin-angiotensin system blockers. Renin-angiotensin system blockers are known to increase renal blood flow and decrease proximal tubular sodium reabsorption. Therefore, it is not surprising that they were among the first agents demonstrated to be effective in hypotonic dilutional hyponatremia in heart failure (84, 85) . Up-titration of renin-angiotensin system blockers should always be promoted for this indication if there are no contraindications, such as coexisting renal dysfunction. Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium.
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